However, it is presently impossible to ascertain the clinical prevalence of single-agent MET dependency in EGFR-mutant lung cancer, because genotyping of lung cancers is most often based on DNA sequencing, which would not capture diminished expression of the mutant EGFR allele. Here, EGFR is linked to lung carcinoma.